Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation

The Lancet Neurology

Volumn 16, Issue 11, 2017, Pages 908-916

  Latourelle, Jeanne C ^a   Beste, Michael T ^a   Hadzi, Tiffany C ^a   Miller, Robert E ^a   Oppenheim, Jacob N ^a   Valko, Matthew P ^a   Wuest, Diane M ^a   Church, Bruce W ^a   Khalil, Iya G ^a   Hayete, Boris ^a   Venuto, Charles S ^b  

^a GNS Healthcare   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; PLACEBO;

ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SIMULATION; FEMALE; FOLLOW UP; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GENETIC VARIATION; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PARKINSON DISEASE; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; UNIFIED PARKINSON DISEASE RATING SCALE; VALIDATION STUDY; GENETICS; PATHOPHYSIOLOGY;

COHORT STUDIES; FEMALE; HUMANS; MALE; PARKINSON DISEASE;

EID: 85029904077     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(17)30328-9     Document Type: Article

References (43)

1. Kalia, LV, Lang, AE, Parkinson's disease. Lancet 386 (2015), 896–912.
2. Sieber, B-A, Landis, S, Koroshetz, W, et al. Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's Disease 2014 conference. Ann Neurol 76 (2014), 469–472.
3. Post, B, Merkus, MP, de Haan, RJ, Speelman, JD, on behalf of the CARPA Study Group. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 22 (2007), 1839–1851.
4. Reinoso, G, Allen, JC, Au, W-L, Seah, S-H, Tay, K-Y, Tan, LCS, Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study. Eur J Neurol 22 (2015), 457–463.
5. Terrelonge, M, Marder, KS, Weintraub, D, Alcalay, RN, CSF β-amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. J Mol Neurosci 58 (2016), 88–92.
6. Morales, DA, Vives-Gilabert, Y, Gómez-Ansón, B, et al. Predicting dementia development in Parkinson's disease using Bayesian network classifiers. Psychiatry Res 213 (2013), 92–98.
7. Schrag, A, Siddiqui, UF, Anastasiou, Z, Weintraub, D, Schott, JM, Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Lancet Neurol 16 (2017), 66–75.
8. Velseboer, DC, de Bie, RMA, Wieske, L, et al. Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Neurology 86 (2016), 986–993.
9. Simuni, T, Long, JD, Caspell-Garcia, C, et al. Predictors of time to initiation of symptomatic therapy in early Parkinson's disease. Ann Clin Transl Neurol 3 (2016), 482–494.
10. Bhattaram, VA, Siddiqui, O, Kapcala, LP, Gobburu, JVS, Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J 11 (2009), 456–464.
11. Friedman, N, Koller, D, Being Bayesian about network structure: a Bayesian approach to structure discovery in Bayesian networks. Mach Learn 50 (2003), 95–125.
12. Xing, H, McDonagh, PD, Bienkowska, J, et al. Causal modeling using network ensemble simulations of genetic and gene expression data predicts genes involved in rheumatoid arthritis. PLoS Comput Biol, 7, 2011, e1001105.
13. Anderson, JP, Parikh, JR, Shenfeld, DK, et al. Reverse engineering and evaluation of prediction models for progression to type 2 diabetes: an application of machine learning using electronic health records. J Diabetes Sci Technol 10 (2016), 6–18.
14. Steinberg, GB, Church, BW, McCall, CJ, Scott, AB, Kalis, BP, Novel predictive models for metabolic syndrome risk: a ‘big data’ analytic approach. Am J Manag Care 20 (2014), e221–e228.
15. Marek, K, Jennings, D, Lasch, S, et al. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95 (2011), 629–635.
16. Goetz, CG, Tilley, BC, Shaftman, SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23 (2008), 2129–2170.
17. Pahwa, R, Lyons, KE, Hauser, RA, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord 20 (2014), 142–148.
18. Hauser, RA, Panisset, M, Abbruzzese, G, et al. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 24 (2009), 541–550.
19. Storch, A, Jost, WH, Vieregge, P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 64 (2007), 938–944.
20. Parashos, SA, Luo, S, Biglan, KM, et al. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol 71 (2014), 710–716.
21. Bates, DM, lme4: mixed-effects modeling with R. http://lme4.r-forge.r-project.org/lMMwR/lrgprt.pdf, June 25, 2010 (accessed March 17, 2014).
22. Hindorff, LA, Sethupathy, P, Junkins, HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 106 (2009), 9362–9367.
23. Piñero, J, Queralt-Rosinach, N, Bravo, À, et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. Database, 2015, 2015, bav028.
24. Donoho, D, Tanner, J, Observed universality of phase transitions in high-dimensional geometry, with implications for modern data analysis and signal processing. Philos Trans A Math Phys Eng Sci 367 (2009), 4273–4293.
25. Ravina, B, Tanner, C, Dieuliis, D, et al. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord 24 (2009), 2081–2090.
26. Hayete, B, Valko, M, Greenfield, A, Yan, R, MDL-motivated compression of GLM ensembles increases interpretability and retains predictive power. http://arxiv.org/abs/1611.06800, Nov 21, 2016 (accessed Dec 21, 2016).
27. Nutt, JG, Holford, NH, The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 39 (1996), 561–573.
28. Venuto, CS, Potter, NB, Ray Dorsey, E, Kieburtz, K, A review of disease progression models of Parkinson's disease and applications in clinical trials. Mov Disord 31 (2016), 947–956.
29. Ravina, B, Marek, K, Eberly, S, et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord 27 (2012), 1392–1397.
30. Kang, J-H, Irwin, DJ, Chen-Plotkin, AS, et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70 (2013), 1277–1287.
31. Gillies, GE, Pienaar, IS, Vohra, S, Qamhawi, Z, Sex differences in Parkinson's disease. Front Neuroendocrinol 35 (2014), 370–384.
32. Carim-Todd, L, Escarceller, M, Estivill, X, Sumoy, L, LRRN6A/LERN1 (leucine-rich repeat neuronal protein 1), a novel gene with enriched expression in limbic system and neocortex. Eur J Neurosci 18 (2003), 3167–3182.
33. Laurén, J, Airaksinen, MS, Saarma, M, Timmusk, T, A novel gene family encoding leucine-rich repeat transmembrane proteins differentially expressed in the nervous system. Genomics 81 (2003), 411–421.
34. MacLeod, D, Dowman, J, Ha mmond, R, Leete, T, Inoue, K, Abeliovich, A, The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52 (2006), 587–593.
35. Inoue, H, Lin, L, Lee, X, et al. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci USA 104 (2007), 14430–14435.
36. Mi, S, Miller, RH, Lee, X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 8 (2005), 745–751.
37. Li, W, Walus, L, Rabacchi, SA, et al. A neutralizing anti-Nogo66 receptor monoclonal antibody reverses inhibition of neurite outgrowth by central nervous system myelin. J Biol Chem 279 (2004), 43780–43788.
38. Vilariño-Güell, C, Wider, C, Ross, OA, et al. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics 11 (2010), 401–408.
39. Nalls, MA, Pankratz, N, Lill, CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 46 (2014), 989–993.
40. Chen, T, Gai, W-P, Abbott, CA, Dipeptidyl peptidase 10 (DPP10(789)): a voltage gated potassium channel associated protein is abnormally expressed in Alzheimer's and other neurodegenerative diseases. BioMed Res Int, 2014, 2014, 209398.
41. Luo, S, Wang, J, Bayesian hierarchical model for multiple repeated measures and survival data: an application to Parkinson's disease. Stat Med 33 (2014), 4279–4291.
42. van den Hout, A, Matthews, FE, Estimating dementia-free life expectancy for Parkinson's patients using Bayesian inference and microsimulation. Biostatistics 10 (2009), 729–743.
43. Lee, JY, Gobburu, JVS, Bayesian quantitative disease-drug-trial models for Parkinson's disease to guide early drug development. AAPS J 13 (2011), 508–518.